In fact, hrACE2 administration in patients with COVID-19 maintains plasma and tracheal ACE2 activity, thereby causing a marked decrease in angiotensin II concentration and an increase in angiotensin 1-7 and 1-9 levels [25]. Here, ACE2 is linked to COVID-19.